Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy

被引:11
|
作者
Li Yu-feng [1 ,2 ]
Deng Zhi-kui [2 ]
Xuan Heng-bao [2 ]
Zhu Jia-bin [2 ]
Ding Bang-he [2 ]
Liu Xiao-ning [2 ]
Chen Bao-an [1 ]
机构
[1] Southeast Univ, Zhongda Hosp, Dept Haematol, Nanjing 210000, Jiangsu, Peoples R China
[2] First Hosp Huaian, Dept Haematol, Huaian 223300, Jiangsu, Peoples R China
关键词
homoharringtonine; chronic myelogenous leukaemia; long term efficacy; CHRONIC MYELOID-LEUKEMIA; INTERFERON-ALPHA; IMATINIB; RESPONSES; RECOMMENDATIONS; CYTARABINE; I/II;
D O I
10.3760/cma.j.issn.0366-6999.2009.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Homoharringtonine (HHT) is effective in treating late stage chronic myelogenous leukaemia (CIVIL), but little is known about long term maintenance during complete cytogenetic response. Long term efficacy and toxicity profiles of low dose HHT were evaluated in this study. Methods One hundred and six patients with CIVIL received 1.5 mg/m(2) of HHT alone by continuous daily infusion for seven to nine days every four weeks. Of 79 patients in the control group, 31 were treated with interferon alpha (IFN-alpha) and 48 with hydroxycarbamide. For 17 patients who failed to achieve cytogenetic response within 12 months' treatment of IFN-alpha, HHT was administered. Quantitative RT-PCR was used to detect the BCR-ABL mRNA expression in 36 Philadelphia positive CML patients enrolled after 2007. Haematological and cytogenetic responses were evaluated in all patients at the 12th month of follow-up. Long term efficacy was assessed in a follow-up with a median time of 54 months (12 months-98 months). Results After 12 months of therapy, cytogenetic response rate of the HHT IFN-a and hydroxycarbamide groups were 39/106, 14/31 and 3/48, and corresponding molecular cytogenetic response rates 6/18, 3/8 and 0. Of the 17 patients who received HHT as salvage treatment, 6 achieved cytogenetic response (3 major). At the 48 months' follow-up, cytogenetic response was maintained in 32/39 patients treated with HHT Patients who had cytogenetic response in HHT group or treated with IFN-a also showed longer median chronic durations, which were 45 months (12 months-98 months) and 49 months (12 months-92 months) respectively, indicating a longer survival time. Conclusions Low dose HHT alone showed considerable short term and long term efficacy in the treatment of late stage CIVIL. It may also be a good choice for patients who have failed imatinib, IFN-a treatment or haematopoietic stem cell transplantation or cannot afford these treatments. Chin Med J 2009;122(12):1413-1417
引用
收藏
页码:1413 / 1417
页数:5
相关论文
共 50 条
  • [1] Therapy of chronic myelogenous leukemia
    Hochhaus, Andreas
    Fabisch, Christian
    Ernst, Thomas
    ONKOLOGE, 2019, 25 (11): : 971 - 984
  • [2] Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase
    Zhu, Jiabing
    Ding, Banhe
    Li, Yufeng
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1426 - 1429
  • [3] Homoharringtonine for the treatment of chronic myelogenous leukemia
    Quintas-Cardama, Alfonso
    Cortes, Jorge
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (06) : 1029 - 1037
  • [4] Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia
    O'Brien, S
    Talpaz, M
    Cortes, J
    Shan, JQ
    Giles, FJ
    Faderl, S
    Thomas, D
    Garcia-Manero, G
    Mallard, S
    Rios, MB
    Koller, C
    Kornblau, S
    Andreeff, M
    Murgo, A
    Keating, M
    Kantarjian, HM
    CANCER, 2002, 94 (07) : 2024 - 2032
  • [5] Optimizing Therapy for Patients With Chronic Myelogenous Leukemia in Chronic Phase
    Kantarjian, Hagop M.
    Cortes, Jorge
    La Rosee, Paul
    Hochhaus, Andreas
    CANCER, 2010, 116 (06) : 1419 - 1430
  • [6] Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX
    Wu, Jingjing
    Wei, Bin
    Shi, Yuye
    Lu, Xueying
    Ding, Yihan
    Wang, Chunling
    Li, Yufeng
    MOLECULAR MEDICINE REPORTS, 2019, 20 (04) : 3233 - 3239
  • [7] Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    O'Brien, S
    Giles, F
    Talpaz, M
    Cortes, J
    Rios, MB
    Shan, JQ
    Thomas, D
    Andreeff, M
    Kornblau, S
    Fadedl, S
    Garcia-Manero, G
    White, K
    Mallard, S
    Freireich, E
    Kantarjian, HM
    CANCER, 2003, 98 (05) : 888 - 893
  • [8] Blastic phase of chronic myelogenous leukemia
    Esfahani M.K.
    Morris E.L.
    Dutcher J.P.
    Current Treatment Options in Oncology, 2006, 7 (3) : 189 - 199
  • [9] Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment
    Deng, Zhikui
    Li, Yuanyuan
    Li, Yu-feng
    TUMORI, 2015, 101 (03) : 323 - 327
  • [10] Chronic myelogenous leukemia in chronic phase.
    Kurzrock R.
    Kantarjian H.
    Talpaz M.
    Current Treatment Options in Oncology, 2001, 2 (3) : 245 - 252